• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel and Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in -Mutant High-Grade Neuroendocrine Tumor of the Lung.

作者信息

Jiao Yuyan, Liu Ming, Luo Ningning, Guo Hao, Li Jianzhe

机构信息

Department of Oncology, Taian City Central Hospital, Taian, People's Republic of China.

Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, People's Republic of China.

出版信息

JTO Clin Res Rep. 2020 Jul 24;1(4):100079. doi: 10.1016/j.jtocrr.2020.100079. eCollection 2020 Nov.

DOI:10.1016/j.jtocrr.2020.100079
PMID:34589958
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8474472/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9eb7/8474472/ba6c1b77e23b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9eb7/8474472/a24971a5a7cd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9eb7/8474472/9cc275e8cbda/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9eb7/8474472/ba6c1b77e23b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9eb7/8474472/a24971a5a7cd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9eb7/8474472/9cc275e8cbda/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9eb7/8474472/ba6c1b77e23b/gr3.jpg

相似文献

1
Novel and Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in -Mutant High-Grade Neuroendocrine Tumor of the Lung.新型双融合作为肺-突变型高级别神经内分泌肿瘤对一线奥希替尼获得性耐药的潜在机制
JTO Clin Res Rep. 2020 Jul 24;1(4):100079. doi: 10.1016/j.jtocrr.2020.100079. eCollection 2020 Nov.
2
Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.非小细胞肺癌患者 EGFR L858R/T790M 伴 EML4-ALK 融合和 EGFR C797S 顺式突变获得性耐药机制对奥希替尼的耐药。
Anticancer Drugs. 2023 Nov 1;34(10):1146-1150. doi: 10.1097/CAD.0000000000001489. Epub 2022 Dec 23.
3
Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.检测到表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗肺癌后出现的 EML4-ALK 融合突变：一例报告。
Ann Palliat Med. 2022 Jul;11(7):2503-2509. doi: 10.21037/apm-22-744.
4
ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer.ALK 重排作为 EGFR 突变型非小细胞肺癌获得性对奥希替尼耐药的机制。
Thorac Cancer. 2021 Mar;12(6):962-969. doi: 10.1111/1759-7714.13817. Epub 2021 Jan 27.
5
Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report.重排作为转移性肺腺癌对奥希替尼耐药的一种机制：一例报告
JTO Clin Res Rep. 2021 Apr 28;2(6):100179. doi: 10.1016/j.jtocrr.2021.100179. eCollection 2021 Jun.
6
Genomic characterization of a PPP1CB-ALK fusion with fusion gene amplification in a congenital glioblastoma.先天性脑胶质瘤中 PPP1CB-ALK 融合并融合基因扩增的基因组特征
Cancer Genet. 2021 Apr;252-253:37-42. doi: 10.1016/j.cancergen.2020.12.005. Epub 2020 Dec 11.
7
Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.肺腺癌患者存在 EGFR 突变时同时伴有继发性 STRN-ALK、EML4-ALK 双融合变异：一例报告。
Anticancer Drugs. 2021 Sep 1;32(8):890-893. doi: 10.1097/CAD.0000000000001094.
8
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.肺腺癌中一种新型获得性外显子 20 EGFR M766Q 突变介导奥希替尼耐药，但对奈拉替尼和波齐替尼敏感。
J Thorac Oncol. 2019 Nov;14(11):1982-1988. doi: 10.1016/j.jtho.2019.06.015. Epub 2019 Jun 27.
9
Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.获得性EGFR T790M并存及EGFR-TKIs驱动基因耐药阻碍奥希替尼在晚期肺腺癌中的疗效：病例报告
Front Pharmacol. 2022 Apr 6;13:838247. doi: 10.3389/fphar.2022.838247. eCollection 2022.
10
Targeting Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in -Mutant Non-Small-Cell Lung Cancer.将激活作为EGFR酪氨酸激酶抑制剂在KRAS突变型非小细胞肺癌中获得性耐药机制的靶向研究
Pharmaceutics. 2021 Sep 15;13(9):1478. doi: 10.3390/pharmaceutics13091478.

引用本文的文献

1
TTC7A-ALK, a novel ALK fusion variant identified in a patient with metastatic lung adenocarcinoma, exhibits excellent response to crizotinib.TTC7A-ALK是在一名转移性肺腺癌患者中鉴定出的一种新型ALK融合变体，对克唑替尼表现出优异的反应。
Transl Oncol. 2025 Apr;54:102345. doi: 10.1016/j.tranon.2025.102345. Epub 2025 Mar 6.
2
Coexistence of a novel , double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review.一名肺低分化腺癌患者中新型双融合的共存及对阿来替尼的反应：病例报告与文献综述
Front Oncol. 2024 Dec 13;14:1453259. doi: 10.3389/fonc.2024.1453259. eCollection 2024.
3

本文引用的文献

1
Catalog of 5' Fusion Partners in -positive NSCLC Circa 2020.2020年左右阳性非小细胞肺癌中5'融合伙伴目录
JTO Clin Res Rep. 2020 Feb 19;1(1):100015. doi: 10.1016/j.jtocrr.2020.100015. eCollection 2020 Mar.
2
Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.受体酪氨酸激酶融合作为表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）在EGFR突变的非小细胞肺癌中可利用的耐药机制
Trends Cancer. 2019 Nov;5(11):677-692. doi: 10.1016/j.trecan.2019.09.008. Epub 2019 Oct 29.
3
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review.
PLEKHA7-ALK和INPP5D-ALK的伴随双融合揭示了肺腺癌对阿来替尼的良好敏感性：一例报告及文献综述
Discov Oncol. 2024 Feb 20;15(1):43. doi: 10.1007/s12672-024-00899-0.
4
Multi-omics analysis of MRPL-13 as a tumor-promoting marker from pan-cancer to lung adenocarcinoma.MRPL-13 作为一种肿瘤促进标记物的泛癌分析到肺腺癌。
Aging (Albany NY). 2023 Oct 12;15(19):10640-10680. doi: 10.18632/aging.205104.
奥希替尼治疗 EGFR 突变型非小细胞肺癌的耐药机制。
Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30.
4
Acquired and Gene Fusions as Mechanisms of Resistance to Osimertinib in -Mutant Lung Cancers.获得性和基因融合作为EGFR突变型肺癌对奥希替尼耐药的机制
JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00126. Epub 2018 Sep 4.
5
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.受体酪氨酸激酶融合和 BRAF 激酶融合是 EGFR 酪氨酸激酶抑制剂的罕见但可治疗的耐药机制。
J Thorac Oncol. 2018 Sep;13(9):1312-1323. doi: 10.1016/j.jtho.2018.05.027. Epub 2018 Jun 5.
6
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.伴有表皮生长因子受体（EGFR）突变的原发性肺小细胞癌和大细胞神经内分泌癌：对EGFR抑制剂无反应。
Lung Cancer. 2015 Apr;88(1):70-3. doi: 10.1016/j.lungcan.2015.02.003. Epub 2015 Feb 7.